Company News & Events

Oryzon to Present at BioEquity Europe 2013 in Stockholm

17 May 2013

Oryzon announced today that Dr. Carlos Buesa will present the latest advances of its LSD1 program inhematological malignancies at the 14th Bio€quity Europe conference: on May 22-23 at the Sheraton Stockholm in Sweden.

Barcelona - Oryzon’s presentation tospecialized investors will occur on Wednesday, May 22 at 16:00 pm at the Drottningholmsalen A room, under the title “Prospects of LSD1 Inhibitors for the Treatment of Cancer and Neurodegenerative Diseases”. Lysine specific demethylase 1 (LSD1, KDM1A), is an epigenetic modulator able that regulates gene expression bydemethylating histones. LSD1 forms part of protein complexes involved in transcriptional regulation, and mis-regulation of these transcriptional complexes may result in disease.

Click here to see full Press Release.

Share this story